Arch Venture Management, LLC Denali Therapeutics Inc. Transaction History

Arch Venture Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $5.06 Million - $7.24 Million	-312,500 Reduced 45.05%	381,249 $8.18 Million
Q2 2023 Aug 09, 2023	SELL	$23.37 - $32.96 $43.8 Million - $61.8 Million	-1,875,000 Reduced 72.99%	693,749 $20.5 Million
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $24.1 Million - $35.9 Million	-1,100,000 Reduced 29.98%	2,568,749 $59.2 Million
Q3 2022 Nov 10, 2022	SELL	$25.97 - $38.53 $39 Million - $57.8 Million	-1,500,000 Reduced 29.02%	3,668,749 $113 Million
Q2 2022 Aug 15, 2022	BUY	$20.88 - $35.19 $108 Million - $182 Million	5,168,749 New	5,168,749 $152 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Arch Venture Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Arch Venture Management, LLC with notifications on news.